Mymetics Corp (MYMX)

[bow-tie]

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy May 28, 2020
Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer.

However, Tollys’ CEO Vincent Charlon told me that his startup’s cancer immunotherapy stands out with its stability and reproducible manufacturing process.

Charlon said the company is starting with bladder cancer because the tumors are known to be sensitive to cancer immunotherapy, and the treatment can be easily administered via a urethral catheter.

https://www.diwou.com/2020/05/28/french-startup-secures-e2-3m-to-advance-cancer-rna-immunotherapy/